Follow us on Twitter
twitter icon@FreshPatents


Infectious patents

      

This page is updated frequently with new Infectious-related patent applications.

SALE: 260+ Infectious-related patent PDFs



Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting
The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant fc region, wherein said variant fc region comprises at least one amino acid modification relative to a wild-type fc region, which variant fc region binds an fcγr that activates a cellular effector (“fcγractivating,” such as fcγriia or fcγriiia) and an fcγr that inhibits a cellular effector (“fcγrinhibiting,” such as fcγriia) with an altered ratio of affinities relative to the respective binding affinities of such fcγr for the fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by fcγr is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by fcγr is desired (e.g., inflammation, autoimmune disease)..
Macrogenics, Inc.


Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells
The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases.. .
Imnate Sarl


Enterococcus faecalis and/or enterococcus faecium antigen
The present invention generally relates to the field of detecting and preventing infectious diseases caused by enterococcus faecalis and/or enterococcus faecium. More specifically, the invention relates to an enterococcus faecalis and/or enterococcus faecium antigen which comprises at least one unit having the following general formula:.
Universitätsklinikum Freiburg


Inhibitors of trka kinase
The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (ngf) receptor trka such as pain, inflammation or an inflammatory diseases, cancer, atherosclerosis, restenosis, thrombosis, neurodegenerative diseases, erectile dysfunction (ed), skin disorders, autoimmune disease like multiple sclerosis, sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination..
Gvk Biosciences Private Limited


Compounds, compositions and associated methods comprising 3-aryl quinolines
Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed..
The United States Government As Represented By The Department Of Veterans Affairs


Sanitizing apparatus support
The present disclosure presents sanitization devices and methods. More particularly, the disclosure presents devices and methods that significantly reduce or eliminate the activity of germs, bacteria and/or other infectious microorganisms from a variety of objects.
Sanitizall Corp.


Adaptation of attenuated infectious bronchitis virus (ibv) to embryonic kidney cells and vaccine thereby produced
Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (ibv). The methods typically include passing a heterogeneous attenuated population of ibv in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of ibv in embryonated chicken eggs (ece) in order to obtain passaged attenuated population of ibv.
Auburn University


Rna virus attenuation by alteration of mutational robustness and sequence space
The application generally relates to the attenuation of a rna virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said rna virus or clone. The means of the application are more particularly dedicated to the attenuation of an infectious rna virus or clone, for the production of immunogenic composition or vaccine.
Institut Pasteur


Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent
A lactic acid bacterium-containing composition including a lactic acid bacterium having a human papillomavirus (hpv) e7 protein-derived polypeptide on a surface thereof, wherein the hpv e7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×108 lactic acid bacteria; a therapeutic oral pharmaceutical composition for at least one of an hpv infectious disease and an hpv-associated tumor which includes the lactic acid bacterium-containing composition; and a mucosal immunity-inducing agent which includes the lactic acid bacterium-containing composition.. .
Japan Health Sciences Foundation


Use of prostacyclin antagonists for treating ocular surface nociception
The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort..
Jenivision Inc.


Non-streaking durable composition for cleaning and disinfecting hard surfaces

The present invention relates to quaternary ammonium disinfecting cleaning compositions comprising a quaternary ammonium compound, an alkyl a polyglycoside with a cmc greater than 1000 ppm and a chelant. Beneficially, the compositions provide residual sanitizing efficacy without diminished performance and without scale formation when diluted with hard water.
Ecolab Usa Inc.

Cyclic dinucleotides useful for the treatment of inter alia cancer

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Oxathiazole thiazolium hsp 70 inhibitors

Provided herein are compounds of formula (i) which are, inter alia, useful allosteric inhibitors of hsp70. The compounds and methods provided are useful for the treatment of cancer, infectious and neurodegenerative diseases..
The Regents Of The University Of California

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.
Tarveda Therapeutics, Inc.

Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases.
Riken

Stable formulations for the oral administration of amphotericin b and related methods

The present invention provides oral ampb and/or protease inhibitor formulations and their use to treat infectious disease, including hiv.. .
Ico Therapeutics Inc.

Therapeutic agent for keratoconjunctive disorders

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a rarγ agonist as an active ingredient is provided.
Yamaguchi University

Methods for immunomodulation of cancer and infectious disease therapy

The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (trip) compound with an effective amount of the therapeutic agent. In particular embodiments, the trip compound enhances the immune response of the subject to the therapeutic agent.
The Regents Of The University Of California

Method for identifying pathogens of bacterial infectious diseases by using bacteria-derived nanovesicles

The present invention relates to a method for predicting causative factors (bacteria) of serious bacterial infectious diseases in a clinical sample containing bacteria-derived nano-sized extracellular vesicles, that is, nanovesicles, through the analysis of the genes contained in the nanovesicles. According to the present invention, information on bacteria of serious bacterial infection can be provided, a causative factor of the bacterial infection can be predicted, and the resistance of the bacteria to antibiotics can be predicted..
Md Healthcare Inc.

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.. .
Duke University

Novel compound and antiviral agent containing same as active ingredient

An object of the invention is to provide a compound that can be utilized as an antiviral agent, in particular as an anti-rna viral agent, and especially as an anti-rs viral agent. The invention provides a compound indicated by formula (1), wherein r1 each independently represent hydrogen, halogen, hydroxyl, amino, carboxyl, c1-c6 alkyl, c1-c6 alkoxyl, c1-c6 halogenoalkyl, c1-c6 alkoxycarbonyl, c1-c6 alkylamino, c2-c5 alkenyl, c3-c6 cycloalkyl, or optionally substituted aryl; r2 each independently represent hydrogen, c1-c6 alkyl, c1-c6 halogenoalkyl, c2-c5 alkenyl, c3-c6 cycloalkyl, optionally substituted aryl or heterocyclic group; and one or more r1 may be present in the same ring, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture of these.
National University Corporation Chiba University

Method for preparing a vaccine antigen, resulting vaccine antigen and uses

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (ii): wherein: x is a —(ch2)-co2y group and y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (ii) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine.
Inserm

Recombinant aav production in mammalian cells

The present invention includes methods and compositions for the production of high titer recombinant adeno-associated virus (raav) in a variety of mammalian cells. The disclosed raav are useful in gene therapy applications.
University Of Florida Research Foundation Incorporated

Cd47 targeted therapies for the treatment of infectious disease

Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of cd47 on a infected cell to sirpα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.. .
The Regents Of The University Of California

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Novel synthetic biology-based adcc technologies are provided that enhance or enable adcc responses, for example, through a rationally-designed soluble universal adcc enhancer protein (suaep) where a high-affinity cd3-binding domain is fused to a high-affinity fc-binding domain. The suaep technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable..
1globe Biomedical Co., Ltd.

Infectious waste disposal

A system for treating infectious waste is provided that employs a medical waste handling and shredding sub-system that feeds partially processed waste to an oxidizer to eliminate potential airborne infectious waste prior to transforming the medical waste into useful co-products. Medical waste is transformed into value added products including hydrocarbon based gases, hydrocarbon-based liquids, carbonized material, and recovered precious metals and rare earth materials in a system having as its transformative element an anerobic, negative pressure, or carbonization system.
Aemerge Llc

Vaccine against infectious bronchitis virus

Embodiments of the present invention relate to an infectious bronchitis virus (ibv) and an immunogenic composition comprising an ibv, respectively, wherein the orf 3a and/or the orf 3b and/or the orf 5a and/or the orf 5b is inactivated. Furthermore, aspects of the present invention relate to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention.
Boehringer Ingelheim Vetmedica Gmbh

Peptidomimetic macrocycles and uses thereof

Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disorders, for example, for treatment of infectious diseases.. .
Aileron Therapeutics, Inc.

Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis

The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-pd-l1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.. .
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Compositions and methods related to viral vaccines

Provided herein are methods and compositions relating to infectious bursal disease virus (ibdv), and vaccines for treatment and prevention thereof.. .
Ohio State Innovation Foundation

Subunit immersion vaccines for fish

The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is f. Psychrophilum and/or infectious pancreatic necrosis virus (ipnv)..
Fvg Limited

Quaternary disinfectant composition with anionic scale inhibiting agent

The present invention relates to quaternary ammonium disinfecting cleaner compositions comprising a quaternary ammonium compound, an antimicrobial amine, and an anionic scale inhibitor. Beneficially, the compositions provide sanitizing efficacy without diminished performance and without scale formation when diluted with hard water.
Ecolab Usa Inc.

Devices, systems and methods to detect viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives

Various devices, systems and methods for detecting infectious agents or determining a susceptibility of an infectious agent to an anti-infective are described herein. One example method comprises introducing a fluid sample to a surface; exposing the surface to a solution; sampling the solution after exposing the solution to the surface; and detecting a change in an electrical characteristic of a sensing device exposed to the solution sampled corresponding to a presence of the infectious agent in the fluid sample..
Avails Medical, Inc.

Bandages for supplying ozone therapy

The present disclosure relates to a bandage wherein the bandage comprise of a first layer of protective covering, wherein the first layer is removable; a second layer of covering, wherein the second layer of covering is made of a cloth material; a third layer of covering, wherein the third layer is the top most layer of the bandage and together with the second layer forms a support pad; an injection, wherein the injection is present on the second layer of covering; a cylinder, wherein the cylinder is present in the support pad, wherein the bandage is used for delivering a medication to a localized area on a patient's body. The bandage is further used for delivering localized, painless ozone gas treatment to a patient suffering from infectious disease.
Umm-al-qura University

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Methods for making novel antigen binding domains

The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel cars that utilize the novel antigen binding domains as an extracellular element.
Chimera Bioengineering, Inc.

Methods and compositions for the activation of gamma-delta t-cells

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
American Gene Technologies International Inc.

Nitroimidazole compound, preparation method therefor and use thereof in drug manufacturing

A nitroimidazole compound represented by general formula (i) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a preparation method therefore, and use thereof in manufacturing drugs for the treating infectious diseases caused by mycobacterium tuberculosis. Specific groups in general formula (i) are as defined in the specification..
Shanghai Sun-sail Pharmaceutical Science & Technology Co., Ltd.

Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.. .

Microfluidic processing of leukocytes for molecular diagnostic testing

Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas..

Dosage and administration of non-fucosylated anti-cd40 antibodies

This invention relates methods of using a non-fucosylated anti-cd40 antibody for treatment of cancer and chronic infectious diseases.. .
Seattle Genetics, Inc.

Convergent and enantioselective total synthesis of communesin analogs

Or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1-r8 and m, n, r, s, t, and u are as defined herein, is provided. Methods of making such compounds are also disclosed as are methods for the treatment of cancer, various infectious diseases, and abnormal cardiovascular function..

Method for making ice cream

A method for making ice cream including the following steps, performed in the following order: heating the side walls of the processing container to a preset preheating temperature; placing a basic ice cream mixture in the processing chamber after the step of heating the side walls of the processing container to a preset preheating temperature; deactivating any infectious agents which may be present in the basic mixture by activating the thermal treatment system in heating mode for a predetermined time in order to pasteurize the basic mixture inside the processing chamber; keeping the basic mixture, previously subjected to the thermal treatment inside the processing chamber, for a predetermined hold time.. .
Ali S.p.a. - Carpigiani Group

Recombinant viral vectors

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative

Compositions and methods for the treatment of mucositis

The invention relates to the compounds of formula i, formula ii, formula iii, formula iv, formula v, formula vi, formula vii and formula viii, or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, formula ii, formula iii, formula iv, formula v, formula vi, formula vii and formula viii, and methods for the treatment of mucositis may be formulated for oral, mouth wash, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection.
Cellix Bio Private Limited

Dosage regimen for pegylated interferon

A pegylated type i interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 μg dose of the pegylated type i interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.. .
Pharmaessentia Corporation

Method of preparing mirabilitum praeparatum by pure strain fermentation and its applications

The present invention involves a method of preparing mirabilitum praeparatum by pure strain fermentation and its application in treating infectious and inflammatory diseases, as well as health products and cosmetics. The method involves blending the ripe fruit (watermelon) of citrullus lanatus (thumb.) matsumu.et nakai with mirabilite (na2so4.10h2o) according to a certain ratio as culture media and the pure strain penicillium rubens as zymocyte, and then fermenting under a certain temperature.

Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds

Compositions and compounds having nucleoside phosphoramidites, and methods of making the same are provided. The compounds can also have one or more amino groups that each can be positively charged.
Zata Pharmaceuticals, Inc.

Cai-based the localized treatment of uveitis

This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid.
Gen Pharma Holdings, Llc

Icos binding proteins

The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.

Compositions and methods related to viral vaccines

Provided herein are methods and compositions relating to infectious bursal disease virus (ibdv), and vaccines for treatment and prevention thereof.. .

Pyrazolo[1,5-a]pyridine compounds and use thereof

Disclosed in the disclosure are a pyrazolo[1,5-a]pyrideine compound with structural features as shown in formula (i) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (mic) of the compounds is lower than 0.1 μg/ml and partially achieves 0.01 μg/ml, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (mdr-tb) strains.

Compositions and methods to prevent and treat biofilms

Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm.

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.

Monitoring method, information processing apparatus, information processing system, and non-transitory computer readable medium

The present invention provides a monitoring method for infectious diseases. The monitoring method includes: obtaining disease information from a plurality of medical facilities 131, 132, 133, and 134; determining the disease occurrence status for each medical facility based on the disease information and a first criterion related to the disease occurrence status at the medical facility; and generating first area alarm information related to the infectious disease status in a first zone based on the disease occurrence status in the medical facilities associated with the first zone divided by a first area division, and a second criterion related to the disease occurrence status in the first zone..
Sysmex Corporation

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.

Anti-tim-3 antibodies

Anti-tim-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer or infectious disease or t-cell dysfunctional disorders. Bispecific antibodies against tim-3 and other targets are also disclosed, with a preferred embodiment of a bispecific antibody against tim-3 and cd3..
Agency For Science, Technology And Research

Cross reactive siglec antibodies

This invention relates to agents that bind multiple siglecs, including antibodies that neutralize the inhibitory activity of multiple siglec-7 and siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease..
Innate Pharma

14-membered ketolides and methods of their preparation and use

Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macro-cyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided.
President And Fellows Of Harvard College

Methods of modulating immune system responses

Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a tifa activator such heptose-1,7-5 bisphosphate or an analogue or derivative thereof.
The Governing Council Of The University Of Toronto

Combination therapy for the treatment of depression and other non-infectious diseases

The invention relates to methods, uses and compositions for treating non-infectious diseases with a therapeutically effective amount of a pharmaceutical composition comprising methylsulfonylmethane, glucosamine, l-glycine, and vitamin b12 (or a derivative of any one thereof).. .
Eaglepharma Pty Ltd

Formulations of methionine aminopeptidase inhibitors for treating infectious diseases

Provided herein are formulations and co-solvent formulations and methods for treating an infectious disease utilizing the same. The formulations and co-solvent formulations may comprise a hydroxyquinoline analog or its pharmaceutically acceptable salt, a solvent and at least two surfactants.
Texas Southern University

Deuterated o-sulfated beta lactam hydroxamic acids and deuterated n- sulfated beta lactams

Provided herein are deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.. .

Bacterial topoisomerase inhibitors and use thereof

The present invention provides novel compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases..

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Compositions and methods for treating an immunodeficiency virus infection

The present disclosure provides an interfering, conditionally replicating human immunodeficiency virus (hiv) construct; infectious particles comprising the constructs; and compositions comprising the construct or the particle. The constructs, particles, and compositions are useful in methods of reducing hiv viral load in an individual, which methods are also provided..

Methods for expanding t cell populations

The present invention provides methods for expanding populations of t cell. The present invention further provides pharmaceutical compositions comprising the expanded t cells, including, γδ t cells, and use thereof for treating infectious, autoimmune or malignant diseases..

Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

A liquid formulation of (s)—n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.. .

Light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging

The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a mycobacterium tuberculosis (m.
The John Hopkins University

Activation of adaptive immune processes for the treatment of cancers and infectious diseases

Polypeptides, such as a multi-valent polypeptide designated svd2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. Svd2 demonstrated in vivo activity in a syngeneic mouse model.
Susavion Biosciences, Inc.

Pyrazolopyrimidine compounds

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Distinction of infectious virus based on molecular biomarker and neutralization of virus causing food poisoning

Discloses are a method for detecting norovirus using a norovirus animal model, a method for screening an antivial agent against norovirus, and a composition for neutralizing the infection with an enteric virus, containing concanavalin a as an active ingredient, so that the method for detecting norovirus can allow the distinction between infectious norovirus and non-infectious norovirus, and the composition can neutralize a virus causing food poisoning.. .
Korea Basic Science Institute

Method for rapidly determining effective sterilization , deimmunization, and/or disinfection

A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device.
Oneightyºc Technologies Corporation

Immunomodulators

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Immunomodulators

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Antibodies to tigit

The invention provides monoclonal antibodies that specifically bind to tigit. The monoclonal antibodies have the capacity for substantial activation of t cells and natural killer cells by inhibiting binding of tigit to cd155.
Abmuno Therapeutics Llc

Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease

The invention relates to the field of cell therapy, particularly nk cell mediated therapy associated with antibodies. The present invention is directed to methods and compositions for increasing the efficiency of therapeutic natural killer cells (nk cells) and/or antibodies, wherein said methods or compositions comprise the use of pooled nk cells from umbilical cord blood units (ucbs), preferably alloreactive nk cells, in combination with a therapeutic antibody in order to enhance the efficiency of the treatment in human subjects, in particularly through an increase in antibody-dependent cell-mediated cytotoxicity (adcc) mechanism.
Emercell Sas

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Benzazepine sulfonamide compounds

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Method for analyzing health signal to respond to infectious disease and apparatus thereof

A method and an apparatus for analyzing a biosignal to respond to an infectious disease are provided. An analyzing method involves receiving biosignals of users of terminals and location information of the terminals, determining infectiousness of a condition of a user among the users by analyzing the location information and the biosignals, and transmitting feedback information regarding the infectiousness of the condition to one or more of the terminals..
Samsung Electronics Co., Ltd.

Production pluripotent stem cells having antigen-specific t cell receptor gene

(2) inducing t cell progenitors or mature t cells from the pluripotent stem cells provided in step (1). Pluripotent stem cells may preferably be ips cells.

Methionine analogs and methods of using same

Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties.
Bioxiness Pharmaceuticals, Inc.

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Pharmaceutical formulations that form gel in situ

The present invention provides aqueous formulations containing an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a ph regulator, and water, wherein a gel containing the therapeutic agent is formed in situ upon instillation of the formulations onto the skin and a body cavity of a subject. The formulations of this invention are useful for treating infectious diseases of skin or a body cavity (e.g., eye, nose, or vagina) of a subject..
Iview Therapeutics, Inc.

A novel synergistic herbal formulation for degenerative disease cardiovascular diseases, autoimmune, inflammatory and metabolism disorder and the process of preparing the same

The present invention relates to a novel synergistic herbal formulation for degenerative disease, cardiovascular diseases, autoimmune, inflammatory and infectious diseases and metabolism disorder etc. Of man, animal and plants more particularly, the present invention relates to the herbal formulation for degenerative disease, cardiovascular diseases, autoimmune, inflammatory and infectious diseases etc which is prepared by using preparation of pongamia pinnata, dalbergia sissoo (shishu) and syzygium aromaticum (clove) which is used as directly and neuro pathways.

Prevention and treatment of microbial infections

Compositions for prevention and treatment of microbial infectious, such as microbial infections that comprise a biofilm, or a microbe that is capable of forming a biofilm are described. The compositions comprise an enzyme that is able to convert a substrate to release hydrogen peroxide and a substance that includes a substrate for the enzyme.
Matoke Holdings Limited

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum.
Sapporo Medical University

Drug delivery system and treating ocular diseases in animals

The present invention relates in general to the field of drug delivery systems for treating ocular diseases in animals, and more specifically, to a drug delivery system and method of treating infectious bovine keratoconjunctivitis (“ibk”) in cattle, commonly known as “pinkeye.” the drug delivery system and method may include a contact lens that has been infused with drugs for treating ibk, such as oxytetracycline, penicillin, streptomycin, tetracycline, gentamicin, cloxacillin or combinations thereof. The medicated contact lens may be placed in contact with the cornea and/or conjunctiva of the afflicted eye of the animal.

Methods and rapid detection of infectious microorganisms

An array of micro-chambers (220) with isfets (300) disposed therein for monitoring single cell activity in the microarray to determine the presence or absence of microorganisms in a sample (390).. .
Becton, Dickinson And Company

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Thienopyrroles as histone demethylase inhibitors

The present application relates to thienopyrrole derivatives, compounds of formulas (i) and (ia), wherein r, r1, r2 and r3 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting kdm1 and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity..
Istituto Europeo Di Oncologia S.r.l.

Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Presently provided are inhibitors of ido and tdo and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.. .
Newlink Genetics Corporation

Emulsified vaccine to obtain formulations of concentrated igy immunoglobulins; processes and uses for the same

The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.. .
Investiacion Aplicada, S.a. De C.v.

Protective covering for preexisting affixed medical equipment safety straps

A disposable cover used to protect preexisting affixed safety straps on medical equipment. The cover includes: 2 protective panels and hoop and loop fasteners on the inside for securing the cover to the preexisting affixed strap and hook and loop fasteners on the outer surface to allow the cover to secure to the opposing cover.

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule.
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Immunomodulators

The present disclosure provides novel macrocyclic compounds which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Organic vaccination an alternative method to traditional preventative vaccination

The disclosed method provides an alternative approach of preventative vaccination which consists primarily of extracting and purifying monocytes, naive t and b lymphocytes from a patient and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are created with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject.

Protein-chaperoned t-cell vaccines

Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone.
Massachusetts Institute Of Technology

Devices and methods for using endovascular cooling to treat septic shock and other disorders

Apparatus, systems and methods for cooling or warming the temperature of all or a portion of the body of a human or animal subject to treat disorders including but not limited to sepsis, septic shock or other inflammatory or infectious conditions which can result in shock, hypoxia, ischemia and/or multiple organ failure in human or animal subjects.. .
Zoll Circulation, Inc.

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Antibody molecules to pd-1 and uses thereof

Antibody molecules that specifically bind to pd-1 are disclosed. The anti-pd-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders..
President And Fellows Of Harvard College

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Infectious hepatitis c viruses of genotype 3a and 4a and uses thereof

The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis c virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis c viruses of either genotype 3a (strain s52) or genotype 4a (strain ed43).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Anti-tim-3 antibodies

Anti-tim-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or t-cell dysfunctional disorders. Bispecific antibodies against tim-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against tim-3 and cd3..
Agency For Science, Technology And Research

Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof.
Regeneron Pharmaceuticals, Inc.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Compositions for the treatment of peritonitis

The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.. .
Reponex Pharmaceuticals Aps

Immunological reagents

This disclosure relates to binding agents with specificity for programmed cell death 1 (pd-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (hiv)), cancer and/or autoimmunity.. .
Mabquest Sa

Gm-csf and il-4 conjugates, compositions, and methods related thereto

In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of gm-csf and a polypeptide il-4. Typically, the gm-csf and il-4 are connected by a linker, e.g., polypeptide.
Children's Healthcare Of Atlanta, Inc.

Fluorinated benzofuranyl-pyrimidine derivatives containing a suflone group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyperproliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).
Bayer Pharma Aktiengesellschaft

Method and removable catheter visual light therapeutic system

A medical device assembly is provided for removable insertion into a catheter with a lumen. The medical device assembly comprises an electromagnetic radiation (emr) source for providing non-ultraviolet, therapeutic emr having an intensity sufficient to inactivate one or more infectious agents and/or to stimulate healthy cell growth causing a healing effect, and a removable emr conduction system at least partially insertable into and removable from the lumen of the catheter.

An antagonistic pd-1 aptamer and its applications in cancer therapy related applications

Aptamers that bind to and antagonize pd-1 and uses thereof in promoting t cell proliferation, treating cancer or infectious diseases such as hiv infection.. .
National Taiwan University

Her2/neu-specific antibodies and methods of using same

This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Novel compounds for the treatment of infectious diseases

Wherein r1, r2, r3, r4, r5 and r6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.. .

4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

The present invention relates to 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (i) or (ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i) or (ia)..
Bayer Intellectual Property Gmbh

Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors

Compounds of formula i: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where r1, r2, ra, rb, rc, rd, x, y, b, and ring c are as defined herein, and wherein the y—b moiety and the nh—c(═x)—nh moiety are in the trans configuration, are inhibitors of trka kinase and are useful in the treatment of diseases which can be treated with a trka kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma Inc.



Infectious topics:
  • Infectious
  • Infectious Disease
  • Infectious Diseases
  • Autoimmune
  • Autoimmune Disease
  • Immune Disease
  • Modulation
  • Nucleotide
  • Killer Cells
  • Natural Killer Cell
  • Stem Cells
  • Amplification
  • Dna Sequence
  • Single Nucleotide Polymorphism
  • Nucleic Acid


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Infectious for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Infectious with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.5775

    file did exist - 13265

    0 - 1 - 260